Cancer Genetics

Cancer Genetics, Inc. (CGI) is an emerging leader in DNA-based cancer diagnostics and services some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also provide a comprehensive range of non-proprietary oncology-focused tests and laboratory services.
CGI’s cutting-edge proprietary tests and state- of-the-art reference laboratory provide critical genomic information to healthcare professionals as well as biopharma and biotech. Our state of the art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State.
The company was founded in 1999 by world-renowned cytogeneticist Dr. R.S.K. Chaganti; and has since built on a foundation of world-class scientific knowledge and IP in solid and blood-borne cancers, while also establishing strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic and the National Cancer Institute.

Company Growth (employees)
Rutherford, US
Size (employees)
223 (est)
Cancer Genetics was founded in 1999 and is headquartered in Rutherford, US

Key People at Cancer Genetics

Panna Sharma

Panna Sharma

President & CEO

Cancer Genetics Office Locations

Cancer Genetics has offices in Rutherford, Morrisville, Los Angeles, Shanghai and in 1 other location
Rutherford, US (HQ)
Complex 201 Route 17 North
Shanghai, CN
Zhong Guo Yi Dong ( Cai Lun Lu )
Los Angeles, US
Health Research Association 1640 Marengo St
Morrisville, US
133 Southcenter Ct

Cancer Genetics Data and Metrics

Cancer Genetics Financial Metrics

Cancer Genetics's revenue was reported to be $27 m in FY, 2016 which is a 50% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

27 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

9.9 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

(15.8 m)

EBIT (FY, 2016)

(16.7 m)

Market capitalization (26-May-2017)

74.7 m

Closing share price (26-May-2017)


Cash (31-Dec-2016)

9.5 m
Cancer Genetics's current market capitalization is $74.7 m.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016


6.6 m10.2 m18 m27 m

Revenue growth, %


Cost of goods sold

4.9 m8.5 m14.1 m17.1 m

Gross profit

1.7 m1.7 m3.9 m9.9 m

Gross profit Margin, %


Operating expense total

10.1 m21 m25.3 m26.7 m


(8.4 m)(18.3 m)(20.7 m)(16.7 m)

EBIT margin, %


Interest expense

(2.4 m)(472.8 k)(344 k)454 k

Interest income

29.7 k73.8 k49 k23 k

Pre tax profit

(13 m)(19 m)(21.4 m)(15.8 m)

Income tax expense

(663.9 k)(2.4 m)

Net Income

(12.4 m)(16.6 m)(20.2 m)(15.8 m)
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016


49.5 m25.6 m19.5 m9.5 m

Accounts Receivable


Current Assets

51.9 m31.8 m28.2 m23.4 m


1.3 m4.4 m6.1 m4.7 m


3 m12 m12 m

Total Assets

55.2 m47.1 m48.9 m42.4 m

Accounts Payable

2.3 m3.8 m7.6 m8.1 m

Current Liabilities

8.6 m4.4 m9.9 m11 m

Preferred Stock

Additional Paid-in Capital

106.8 m112.5 m131.2 m139.6 m

Retained Earnings

(61.3 m)(98.2 m)(114 m)

Total Equity

45.5 m33 m25.6 m

Financial Leverage

1.2 x1.5 x1.7 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(12.4 m)(16.6 m)(20.2 m)(15.8 m)

Depreciation and Amortization

311.2 k810.2 k1.5 m2 m

Accounts Receivable

(716.5 k)(1.7 m)(1.7 m)(5.9 m)


Accounts Payable

Cash From Operating Activities

48.6 m(23.9 m)(6.1 m)

Purchases of PP&E

(257.3 k)(1.4 m)(1 m)(490 k)

Cash From Investing Activities

(1.4 m)(11.4 m)(2.6 m)(609 k)

Short-term Borrowings

(3.6 m)(408.4 k)(1.3 m)

Cash From Financing Activities

58.1 m10.1 m8.5 m

Interest Paid

608.1 k128.4 k240 k333 k
Y, 2016

Financial Leverage

1.7 x

Cancer Genetics Market Value History

Cancer Genetics Job Categories

Cancer Genetics Online and Social Media Presence

Cancer Genetics News and Updates

Cancer Genetics Company Life and Culture

You may also be interested in